The angina market is encountering growth because of the rising pervasiveness of angina pectoris universally. Factors, for example, maturing populations, rising frequency of cardiovascular risk factors like hypertension and diabetes, and objectionable lifestyle propensities add to the rising predominance of angina, driving interest for indicative and treatment choices.
Risk explanation assumes a critical part in directing treatment choices and improving results for patients with angina. Medical services suppliers use risk appraisal devices and scoring frameworks, to separate patients in view of their cardiovascular risk profile, directing customized therapy techniques custom-made to individual patient requirements and chance levels.
There is a developing pattern towards harmless treatment choices for angina, focused on side effect help and working on personal satisfaction for patients. Harmless medicines like lifestyle alterations, pharmacological treatments, and heart recovery programs offer powerful management techniques for angina while limiting the requirement for intrusive methodology or medical procedures, upgrading patient solace and adherence to therapy plans.
Pharmacological treatments assume a focal part in the management of angina, planning to lessen myocardial ischemia, reduce side effects, and further develop practice resistance in patients. Progresses in pharmacological treatments incorporate the advancement of new antianginal drugs, for example, calcium channel blockers, beta-blockers, nitrates, and ranolazine, offering extra treatment choices and further developed viability for patients with angina.
Lifestyle changes are fundamental parts of angina management, focusing in on risk factor alteration and auxiliary avoidance procedures. Medical services suppliers underline the significance of lifestyle mediations like smoking cessation, dietary changes, normal activity, weight management, and stress decrease procedures in lessening cardiovascular risk and further developing results for patients with angina.
The reception of telemedicine stages and distant conferences is expanding in the management of angina, giving helpful admittance to cardiovascular consideration for patients with angina. Teleconsultations empower patients to talk with cardiologists from a distance, examine side effects, get treatment proposals, and go through remote observing of their condition, further developing admittance to mind and patient fulfillment.
The angina marketis anticipated to reach USD 1.63 Billion by 2030 at 5.50% CAGR during the forecast period 2022-2030.
Angina is a significant symptom of the coronary artery disease and is described as squeezing, tightness, and heaviness of the chest. It is a type of chest pain, which is caused by a reduced flow of blood to the heart. Fatigue, shortness of breath, nausea, and sweating are some of the common symptoms of angina. The increasing prevalence of angina and the growing healthcare expenditure are the major drivers for the market growth. According to the report of the American Heart Association of 2016, the prevalence of angina in West Virginia was estimated to be around 6.2% and around 2.3% in Hawaii. Moreover, the growing geriatric and obese population followed by the increasing prevalence of coronary heart diseases provide favorable backgrounds for market growth. According to the World Health Organization, the total number of people who age 65 or more is projected to increase from 524 million in 2010 to approximately 1.5 billion by 2050. Additionally, according to a study published in the Annals of Translational Medicine Journal approximately 15.5 million people who aged 20 years or more within the U.S. suffered from the coronary heart disease, in 2016. However, factors such as low per capita healthcare expenditure and high cost for therapeutic procedures such as coronary bypass surgery are estimated to restraint the market growth during the forecast period. According to a study published by the Brazilian Journal of Cardiovascular Surgery in 2017, the average total cost for coronary bypass surgery was estimated to be ~USD 7,992.
Intended Audience
Segmentation
The angina Market is segmented on the basis of type, diagnosis, treatment, and end-user.
On the basis of type, the market is segmented into angina pectoris, unstable angina, prinzmetal angina, and others. On the basis of diagnosis, the market is categorized into imaging, blood test, stress test, and others. The imaging segment is sub-segmented into electrocardiogram, chest X-ray, cardiac computerized tomography scan, cardiac MRI, and others. The blood test segment is sub-segmented into cholesterol test, low-density lipoprotein test, triglycerides test, and others. On the basis of treatment, the market is segmented into lifestyle changes, medications, angioplasty and stenting, coronary bypass surgery, and others. The medication segment is sub-segmented into aspirin, clot-preventing drugs, statins, ranolazine, and others. The clot-preventing drugs segment is further segmented into clopidogrel, prasugrel, and others. On the basis of end-user, the Angina Market is segmented into hospitals and clinics, diagnostic centers, academic institutes, and others.
Research Methodology
Â
Sources: WHO, American Heart Association, Annals of Translational Medicine, Brazilian Journal of Cardiovascular Surgery, Annual Reports, Press Release, White Paper, and Company Presentation
Regional Analysis
America dominates the angina market owing to a well-developed healthcare sector, growing healthcare expenditure, and a huge patient population for coronary heart diseases. Moreover, global players such as Merck & Co., Inc. and Baxter within the region fuel the market growth.
Europe is the second largest market for angina. Factors such as availability of funds for research, growing number of obese and patient population, followed by the presence of developed economies such as France, Italy, and Germany within the region provide favorable backgrounds for regional market growth. According to the Eurostat in 2016, it was estimated that more than half of the adult population (51.6%) within the European Union was over-weight.
Asia Pacific is estimated to be the fastest growing region for the angina market owing to the presence of developing economies such as India and China and a developing healthcare sector. Moreover, rising healthcare expenditure and favorable government policies are expected to boost the Angina Market growth during the forecast period.
The Middle East and Africa holds the least share in the angina market, owing to the presence of poor economies, stringent government policies, and low per capita healthcare expenditure, especially within the African region. A majority of the market of the region is held by the Middle East owing to the increasing healthcare expenditure and presence of developed economies such as Saudi Arabia, Kuwait, and Qatar within the region.
Key players in the Angina Market
Anthera (U.S.), Taxus Cardium (U.S.), Astellas Pharma (Japan), Sanofi (France), Bayer AG (Germany), Merck & Co., Inc. (U.S.), Torrent Pharmaceuticals Limited (India), Huya Bioscience International (U.S.), Viromed Co. Ltd. (South Korea), Baxter (U.S.), and others.
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)